Disease Landscape and Forecast Insights

In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…

In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3…

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases. Even though physicians’ understanding of the disease’s pathophysiology…

As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have…

In 2023, sales of branded biologics in immunology exceeded $64 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…

In 2023, sales of branded biologics for oncology, immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $150 billion in the major pharmaceutical…

In 2023, sales of branded MAb biologics in neurology exceeded $10 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, the…

Schizophrenia is a highly drug-treated condition that uses an array of medications, including atypical and typical antipsychotics, resulting in a complex treatment algorithm. Although this drug…

Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…

The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…